Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA

Clinical and Vaccine Immunology

Volumn 22, Issue 2, 2015, Pages 235-244

  Struyf, Frank ^a   Colau, Brigitte ^a   Wheeler, Cosette M ^b   Naud, Paulo ^c   Garland, Suzanne ^d,e   Quint, Wim ^f   Chow, Song Nan ^g   Salmerón, Jorge ^h   Lehtinen, Matti ^i,m   Del Rosario Raymundo, M Rowena ^j   Paavonen, Jorma ^k   Teixeira, Júlio C ^l   Maria Julieta Germar, Maria Julieta ^m   Peters, Klaus ^n,q   Skinner, Rachel ^o   Limson, Genara ^m   Castellsagué, Xavier ^p   Poppe, Willy A J ^q   Ramjattan, Brian ^r   Klein, Terry D ^s   Schwarz, Tino F ^t   Chatterjee, Archana ^u   Tjalma, Wiebren A A ^v   Diaz Mitoma, Francisco ^w   Lewis, David J M ^x   Harper, Diane M ^y   Molijn, Anco ^f   Van Doorn, Leen Jan ^f   David, Marie Pierre ^a   Dubin, Gary ^z   more..

^a GSK   (Belgium)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f DDL DIAGNOSTIC LABORATORY   (Netherlands)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

ⁱ UNIVERSITY OF TAMPERE   (Finland)

^j San Pablo Colleges Medical Center   (Philippines)

^k UNIVERSITY OF HELSINKI   (Finland)

^l UNIVERSITY OF CAMPINAS   (Brazil)

^m UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

ⁿ Facharzt für Frauenheilkunde und Geburtshilfe   (Germany)

^o UNIVERSITY OF SYDNEY   (Australia)

^p CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r First Line Medical Services Ltd St john'S Newfoundland and Labrador   (Canada)

^s Agronomic Services   (United States)

^t UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^u UNIVERSITY OF SOUTH DAKOTA   (United States)

^v Multidisciplinary Breast Clinic Gynecological Oncology Unit Department of Obstetrics and Gynecology   (Belgium)

^w Advanced Medical Research Institute of Canada   (Canada)

^x UNIVERSITY OF SURREY   (United Kingdom)

^y DARTMOUTH MEDICAL SCHOOL   (United States)

^z GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE; ALUMINUM HYDROXIDE; ASO4 MIXTURE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; IMMUNOLOGICAL ADJUVANT; LIPID A;

ADOLESCENT; ADULT; ALGORITHM; ALTERNATIVE TESTING ALGORITHM; ARTICLE; ASSAY; COHORT ANALYSIS; CONTROLLED STUDY; DNA ENZYME IMMUNOASSAY; DRUG EFFICACY; ENZYME IMMUNOASSAY; EXPLORATORY RESEARCH; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HYBRIDIZATION; INCIDENT INFECTION; INFECTION; LINE PROBE ASSAY; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; POST HOC ANALYSIS; RETROSPECTIVE STUDY; REVERSE HYBRIDIZATION ASSAY; ANALOGS AND DERIVATIVES; CLASSIFICATION; GENETICS; GENOTYPE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; LIPID A; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921984041     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00457-14     Document Type: Article

References (25)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19. Http://dx.doi.org/10.1002/(SICI)1096-9896(199909) 189:1-12::AID-PATH431-3.0.CO;2-F.
2. de Sanjosé S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, et al. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11:1048-1056. Http://dx.doi.org/10.1016 /S1470-2045(10)70230-8.
3. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. 2011. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128:927-935. Http://dx.doi.org/10.1002 /ijc.25396.
4. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM. 2012. Human papillomavirus types in 115,789 HPVpositive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131:2349-2359. Http://dx.doi.org/10.1002/ijc.27485.
5. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K. 2013. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer 132:854-867. Http://dx.doi.org/10.1002/ijc.27713.
6. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. 2009. Safety of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 5:332-340. Http://dx.doi.org/10.4161/hv.5.5.7211.
7. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765. Http://dx.doi.org/10.1016/S0140 -6736(04)17398-4.
8. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255. Http://dx.doi.org/10.1016/S0140-6736(06)68439-0.
9. GlaxoSmithKline Vaccine HPV-007 Study Group. 2009. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374:1975-1985. Http://dx.doi.org/10.1016 /S0140-6736(09)61567-1.
10. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A. 2010. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 28:6247-6255. Http://dx.doi.org/10.1016/j.vaccine.2010.07.007.
11. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsagué X, De Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161- 2170. Http://dx.doi.org/10.1016/S0140-6736(07)60946-5.
12. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, Greenacre M. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314. Http://dx.doi.org/10.1016/S0140-6736(09)61248-4.
13. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G. 2012. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:89-99. Http://dx.doi.org/10.1016/S1470 -2045(11)70286-8.
14. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M. 2012. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year endof- study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:100-110. Http://dx.doi.org/10.1016/S1470-2045(11)70287-X.
15. Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, Coutlee F, Villa LL, Franco EL. 2013. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol 178:625-634. Http://dx.doi.org/10.1093/aje /kwt018.
16. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. 2006. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 44:3292-3298. Http://dx.doi.org/10.1128/JCM.00539-06.
17. Quint WG, Scholte G, van Doorn LJ, Kleter B, Smits PH, Lindeman J. 2001. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping. J Pathol 194:51-58. Http://dx.doi.org/10.1002/path.855.
18. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199:936-944. Http://dx.doi.org/10.1086/597309.
19. van Alewijk D, Kleter B, Vent M, Delroisse JM, de Koning M, van Doorn LJ, Quint W, Colau B. 2013. A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay. J Clin Microbiol 51:1171-1178. Http://dx.doi.org/10.1128 /JCM.02831-12.
20. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, ter Harmsel B, Quint W. 1998. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 153:1731-1739. Http://dx.doi.org/10.1016 /S0002-9440(10)65688-X.
21. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M, Quint W. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37:2508-2517.
22. Tjalma WA, Depuydt CE. 2013. Cervical cancer screening: which HPV test should be used-L1 or E6/E7? Eur J Obstet Gynecol Reprod Biol 170:45-46. Http://dx.doi.org/10.1016/j.ejogrb.2013.06.027.
23. Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, Dubin G, Lehtinen M. 2012. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years postvaccination. Int J Cancer 131:2832-2838. Http://dx.doi.org/10.1002/ijc.27586.
24. Pagliusi SR, Aguado MT. 2004. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23:569-578. Http://dx.doi.org/10.1016/j.vaccine.2004.07.046.
25. World Health Organization Expert Committee on Biological Standardization. 2011. Fifty-seventh report. World Health Organization technical report series 962. World Health Organization, Geneva, Switzerland. Http: //apps.who.int/medicinedocs/documents/s19540en/s19540en.pdf.